|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:compatibleWith
|
type 1 diabetes
|
|
gptkbp:contraindication
|
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
|
|
gptkbp:discoveredIn
|
2000s
|
|
gptkbp:effect
|
weight loss
lower blood glucose
decrease glucagon secretion
increase insulin secretion
reduce appetite
slow gastric emptying
|
|
gptkbp:example
|
gptkb:albiglutide
gptkb:exenatide
gptkb:liraglutide
gptkb:semaglutide
gptkb:dulaglutide
|
|
gptkbp:mechanismOfAction
|
GLP-1 receptor activation
|
|
gptkbp:prescribes
|
endocrinologists
primary care physicians
|
|
gptkbp:regulatorApproval
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:relatedTo
|
incretin mimetics
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
oral (semaglutide)
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
pancreatitis
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
obesity
|
|
gptkbp:bfsParent
|
gptkb:diabetes_mellitus_type_2
gptkb:type_2_diabetes
gptkb:Type_2_diabetes
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GLP-1 receptor agonists
|